Alnylam Pharmaceuticals To Present New Helios-B Clinical Data At American Heart Association Scientific Sessions 2026

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi-powered transthyretin (TTR) silencing with AMVUTTRA® (vutrisiran), including long-term cardiovascular outcomes and functional measures, while providing new insights into the multisystemic manifestations of transthyretin-mediated amyloidosis (ATTR) and opportunities for earlier diagnosis and treatment.